BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Zars, Inc. Announces FDA Actions On S-Caine Products


10/19/2005 5:10:10 PM

SALT LAKE CITY--(BUSINESS WIRE)--Feb. 26, 2004--ZARS Inc., a privately held Salt Lake City-based pharmaceutical company that develops and markets products for pain, anxiety disorders and nausea, announced today that the Food and Drug Administration has issued a letter of approvability for the company's first product, the S-Caine Patch®. Once this New Drug Application (NDA) is approved, this product will be used to numb quickly the skin of babies, children and adults before painful procedures, such as IV catheter placement, and other minor dermatological interventions. ZARS' partner with this product is Ferndale Laboratories, a Michigan-based dermatological products company. In November of last year ZARS submitted a second NDA for the S-Caine Peel®, a cream that topically numbs larger areas of the skin before painful cosmetic laser procedures, such as facial resurfacing and removal of unwanted hair, spider veins and tattoos. The FDA accepted the S-Caine Peel® NDA submission for filing, and a decision by the agency is expected by mid-September. Johnson & Johnson is ZARS' partner with this product.

ZARS currently has five open INDs and two pending NDAs.

Since its founding as a spinout from the University of Utah in 1997 by Jie Zhang, Ph.D, Michael Ashburn, M.D., Larry Rigby and Theodore Stanley, M.D., ZARS has been developing proprietary skin patches that deliver drugs into and through the skin, using patented CHADD (controlled heat assisted drug delivery) technologies.

Contact:

ZARS Inc., Salt Lake City Larry Rigby, 801-350-0202 Mobile: 801-556-1880 ldr@zars.com www.zars.com

Source: ZARS Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES